New York-based Pfizer Inc. (PFE), with a market capitalization of $144.8 billion, is a global biopharmaceutical company that discovers, develops and markets innovative medicines and vaccines across a variety of therapeutic areas. The streamlined post-sale portfolio focuses on breakthrough treatments in oncology, immunology, rare diseases and infectious diseases.
Companies with a valuation of $10 billion or more are generally classified as “large-cap stocks,” and Pfizer fits this criteria perfectly. Pfizer is focused on addressing unmet medical needs across diverse therapeutic areas with an innovative pipeline of cutting-edge medicines and vaccines, including advancements in mRNA technology such as Comilnati and Paxrobid. And stands out in the market. Additionally, patient-centered initiatives such as the PfizerForAll platform and the Closing the Healthcare Gap Partnership emphasize accessible and equitable care.
However, the pharmaceutical giant is down 20% from its 52-week high of $31.54 hit in July. PFE stock has declined 11.1% over the past three months, less than the 6.3% decline in the Healthcare Select Sector SPDR Fund (XLV) over the same period.
www.barchart.com
Longer term, PFE is down 12.4% on a year-to-date basis, lagging XLV's 7.6% gain. Additionally, Pfizer stock has declined 13.8% over the past 52 weeks, while XLV has returned 11.1% over the same period.
Confirming the bearish trend in price, PFE has been trading below its 50-day and 200-day moving averages since late October.
www.barchart.com
Pfizer on October 29 reported better-than-expected third-quarter 2024 financial results, with adjusted EPS of $1.06 and revenue of $17.7 billion, beating expectations. This growth was driven by better-than-expected revenues from COVID-19 products such as Paxlovid and new launches such as Abrisbo, as well as strong performance from non-COVID-19 products such as Vyndaquel and Eliquis. Additionally, Pfizer raised its full-year revenue outlook to $61 billion to $64 billion and adjusted EPS forecast to $2.75 to $2.95. However, the stock fell 1.4% on the day amid concerns over Chief Executive Albert Bourla's defense of recent acquisitions over criticism from activist investor Starboard Value. cast a shadow.
PFE has also underperformed its biggest rival, Sanofi (SNY), which is up 2.1% over the past 52 weeks and down 3.5% year-to-date.
Despite PFE's weak price performance, analysts are somewhat optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 24 analysts covering the stock, and the average price target of $32.19 represents a 27.6% premium to current levels.
On the date of publication, Sohini Mondal did not have (directly or indirectly) any positions in any securities mentioned in this article. All information and data in this article is for informational purposes only. For more information, please see the Barchart Disclosure Policy here. More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
